دورية أكاديمية
Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study.
| العنوان: | Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study. |
|---|---|
| المؤلفون: | Chen CT; Department of Oncology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan, R.O.C.; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C., Hsu CH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan, R.O.C., Cheng AL; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan, R.O.C.; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan, R.O.C., Shao YY; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.; yuyunshao@gmail.com.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan, R.O.C. |
| المصدر: | Anticancer research [Anticancer Res] 2022 Sep; Vol. 42 (9), pp. 4461-4470. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet ISSN: 1791-7530 (Electronic) Linking ISSN: 02507005 NLM ISO Abbreviation: Anticancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Attiki, Greece : International Institute of Anticancer Research Original Publication: Athens, Greece : Potamitis Press |
| مواضيع طبية MeSH: | Antineoplastic Agents*/therapeutic use , Carcinoma, Hepatocellular*/pathology , Chemoembolization, Therapeutic*/methods , Liver Neoplasms*/pathology, Female ; Humans ; Male ; Middle Aged ; Niacinamide/therapeutic use ; Phenylurea Compounds/therapeutic use ; Retrospective Studies ; Sorafenib/therapeutic use ; Treatment Outcome |
| مستخلص: | Background/aim: The reimbursement criteria of sorafenib for advanced hepatocellular carcinoma (HCC) were expanded in 2016 by Taiwan's National Health Insurance (NHI) to include patients without macrovascular invasion or extrahepatic spread. This study explored sorafenib treatment outcomes before and after this expansion. Patients and Methods: The NHI database was searched for patients who initiated sorafenib treatment between January 1, 2013, and December 31, 2017. Clinical variables were retrieved from the Taiwan Cancer Registry database. Overall survival (OS) and time to treatment discontinuation (TTD) were calculated as the times from the first sorafenib prescription date until death and the final prescription date, respectively. Results: A total of 13,862 patients were included. The median age was 64 years, 78.1% of patients were male. Approximately a quarter of patients (25.1%) received sorafenib after the criteria expansion and exhibited significantly longer OS (median 7.9 vs. 6.6 months, p<0.001) and TTD (median 3.0 vs. 2.6 months, p=0.003) compared with patients who started before. These results were verified in patients with available data regarding clinical prognostic factors (n=9,378, 67.7% of the entire study population). In the multivariate analysis, sorafenib prescription after criteria expansion remained an independent predictor of longer OS [hazard ratio (HR)=0.87, p<0.001] and TTD (HR=0.93, p=0.004). In the subgroup analysis, these trends were consistently observed across different patient subgroups. Conclusion: Patients with HCC who received sorafenib treatment after the reimbursement criteria expansion exhibited longer OS and TTD. (Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.) |
| فهرسة مساهمة: | Keywords: Barcelona Clinic Liver Cancer Stage C; Hepatocellular carcinoma; National Health Insurance; reimbursement criteria; sorafenib; transarterial chemoembolization |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (Phenylurea Compounds) 25X51I8RD4 (Niacinamide) 9ZOQ3TZI87 (Sorafenib) |
| تواريخ الأحداث: | Date Created: 20220830 Date Completed: 20220831 Latest Revision: 20220831 |
| رمز التحديث: | 20231215 |
| DOI: | 10.21873/anticanres.15946 |
| PMID: | 36039431 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1791-7530 |
|---|---|
| DOI: | 10.21873/anticanres.15946 |